BHV-1400
Pipeline Category
Pharmaceutical
Short Description / Indication
BHV-1400 is a first-in-class, antigen-specific TRAP™ extracellular protein degrader developed by Biohaven to treat IgA nephropathy (IgAN).
Licensees
| Company Name | Company Website URL |
|---|---|
| Biohaven | https://www.biohaven.com/ |
Pharmaceutical Status